Biological optimal dosing of anti-neoplastic in order to maximize therapeutic efficacy and safety

2015 Fiscal Year Final Research Report

• Project/Area Number: 24590656
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Applied pharmacology
• Research Institution: Kyoto University
• Principal Investigator: Ishiguro Hiroshi 京都大学, 医学(系)研究科(研究院), 准教授 (20422925)
• Co-Investigator(Kenkyū-buntansha): TOI Masakazu 京都大学, 大学院医学研究科, 教授 (10207516) ; TERAMUKAI Satoshi 京都府立医科大学, 医学研究科, 教授 (20359798)
• Project Period (FY): 2012-04-01 – 2016-03-31
• Keywords: Medical Oncology / Pharamcokinetics / Supportive care

Outline of Final Research Achievements

For anti-cancer treatment, biologically optimal dosing in addition to state of art supportive care in order to aim for best drug efficacy is very important.
We have conducted several clinical trial aiming for better management for chemotherapy-induced nausea and vomiting, molecular targeted drug-related skin rash, 5HT3-induced constipation and published them at the major scientific conference or journal.
We also conducted clinical trial to find out biologially optimal dosing for anti-anti-neoplastics, such as decetaxel, afatinib irinotecan and TS-1. We also published them at the major scientific conference or journal.

Free Research Field

Medical Oncology